A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Summary

This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus. The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo.

Timeline

Start

2006-08-11

Primary completion

2007-02-07

Completion

2007-02-07

Outcome

Met primary endpoint

registry analysis (superiority or other test); MK-0893 (40 mg) vs Placebo; p <0.001; Mean Difference (Final Values) -25.9 (95% CI -38.4 to -13.3); ANCOVA NCT02004886 ↗

registry analysis (superiority or other test); MK-0893 (120 mg) vs Placebo; p <0.001; Median Difference (Final Values) -53.6 (95% CI -66.1 to -41.1); ANCOVA NCT02004886 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-0893	Small molecule	40 mg	—
Subject	MK-0893	Small molecule	120 mg	—
Comparator	Metformin	Small molecule	2000 mg	Oral

Indications